HCV patients treated with sofosbuvir maintained high SVR despite negative predictors

CHICAGO — Hepatitis C virus-infected patients with genotypes 1, 2 or 3 displayed high sustained virologic response rates after being treated with a sofosbuvir-based regimen despite the presence of negative predictors, according to data presented at Digestive Disease Week 2014.

Ira M. Jacobson, MD, chief of the division of gastroenterology and hepatology at Weill Cornell Medical College, New York, and co-chief medical editor of HCV Next, and colleagues performed univariate and multivariate regression analyses on 868 treatment-naive patients. The study included 339 patients with genotype 1 who received sofosbuvir (SOF) with pegylated interferon alfa plus ribavirin (PegIFN/RBV) for 12 weeks, 285 with genotype 2 who were treated with SOF with RBV for 12 weeks, and 244 genotype 3 patients who received 24 weeks SOF with RBV. Researchers sought to identify variables that may be associated with relapse and affected sustained virologic response (SVR) rates.

Ira M. Jacobson

Six negative predictors were associated with relapse among all patients: male sex, weighing at least 75 kg, IL-28B non-cc genotype, cirrhosis, baseline hepatitis C virus (HCV) RNA ≥800,000 IU/mL and previous treatment failure. Ninety percent or more in patients in all genotypes still achieved SVR when they had three or fewer negative predictors. SVR rates declined among patients with five or more negative predictors.

“Sofosbuvir-based regimens were highly effective even in patients with a combination of multiple negative factors, but SVR12 rates were compared to be lower in patients with five or six of the negative predictors,” Jacobson said at the conference.

For more information:

Jacobson IM. #647. Presented at: Digestive Disease Week 2014; May 3-6; Chicago.

Disclosure: Researchers reported numerous financial disclosures.